Eleftherios Mylonakis, MD
Infectious Disease · Houston, TXNPI 1629041074
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,679 of the $3,679 with a category attached, or 100.0%. Shionogi Inc accounts for 68.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $2,520, 7.4 times the $341 reported in 2020.
Across 3 payments — averaging $1226.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$3K
- Seqirus USA Inc$818
- Cepheid$341
Across 140 payments — averaging $45,508 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$5.6M
- Sanofi Pasteur Inc.$518K
- T2 Biosystems, Inc.$112K
- Scynexis, Inc.$74K
- Pfizer$61K
- AstraZeneca$2K
What the payments were for
- Consulting fees$3,679100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 1 | $2,520 |
| Seqirus USA Inc | 1 | $818 |
| Cepheid | 1 | $341 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,679 in reported general payments places this provider in the 75th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.